BOTHELL, Wash., July 9 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) has engaged InCap Group, Inc. (InCap) to provide strategic investment and financial advice and services. CellCyte seeks to build shareholder value by monetizing its two core platform technologies and will work with InCap to initiate a corporate partnering strategy to exploit development and commercialization of CellCyte's cell expander and stem cell delivery technologies.
"We are committed to realizing the value in our two stem cell enabling technologies and look forward to the counsel InCap can provide in this regard as well as their assistance in executing staged capital raises," said Gary A. Reys, President and CEO of CellCyte.
"The promise of stem cells in regenerative medicine has been hampered by the inability to generate sufficient cells and the lack of effective non-invasive ways to deliver them to the therapeutic target. CellCyte's two technology platforms may provide the solutions to both of these fundamental problems. We are excited about helping the Company commercialize its highly leveraged technologies," noted Paul J. Marangos, Ph.D., a consultant with InCap.
CellCyte's strategic initiatives include:
-- Transitioning from a research to a commercialization business approach
-- Establishing a partnering strategy targeting multiple companies involved in the clinical exploitation of stem cells
-- Accelerating the development and commercialization of the company's
cell expander bioreactor technology
-- Staged milestone driven capital formation
About InCap Group
InCap Group, Inc., is an investment banking firm focused on the investment management and securities brokerage industries. They provide merger and acquisition services, capital raising services, valuations and strategic advice to their clients. The value of their services is derived from the market experience of their professionals. The professionals at InCap were deeply involved in many of Legg Mason, Inc.'s investment management acquisitions, which resulted in the firm being transformed from a modest regional securities brokerage firm to one of the ten largest asset management firms in the world. InCap's professionals have worked at other leading industry firms including Fidelity Investments, SEI Investments, PaineWebber, and Oppenheimer & Co. For more information, please visit http://www.incapgroup.com.
About CellCyte Genetics
CellCyte Genetics is a biotechnology company engaged in the discovery,
development and commercialization of stem cell enabling therapeutic
products. CellCyte is developing products to allow more efficient delivery
and increased retention of adult stem cells to diseased organs, such as the
heart. The goal of these therapies is to increase the number of stem cells
delivered to a damaged organ, thereby markedly increasing organ healing and
functional restoration. The Company's lead product, CCG-TH30, is being
developed to send autologous bone marrow-derived (adult) stem cells to the
heart of patients after a heart attack.
For further information see: http://www.cellcyte.com.
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE. EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS, INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH THE RESEARCH AND DEVELOPMENT OF CCG- TH30PRIVATE PLACEMENT OFFERING(S) AND OTHER SERVICES PROVIDED TO CELLCYTE BY INCAP. OTHER RISKS INCLUDE RISKS ASSOCIATED WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE PRODUCTS AND COMPANIES AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY ACHIEVE COMMERCIAL SUCCESS. THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS. ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS, AND INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS, OR INTENTIONS WILL PROVE TO BE ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S PERIODIC REPORTS FILED FROM TIME TO TIME WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST RECENT REPORTS ON FORM 10-KSB AND FORM 10-Q. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE CONTENTS OF THIS NEWS RELEASE.
|SOURCE CellCyte Genetics Corporation|
Copyright©2008 PR Newswire.
All rights reserved